Advertisement

Medical Oncology

, 31:906 | Cite as

Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin)

  • M. GubanskiEmail author
  • B. Glimelius
  • P. A. Lind
Original Paper

Abstract

With a median overall survival of only 9–13 months in patients with advanced gastric cancer (GC), the quality of life (QoL) during the palliative treatment remains a key issue. Furthermore, when combinations of two or three drugs are used, the impact on QoL should be carefully evaluated. This was studied within the GATAC trial in patients sequentially treated with docetaxel and irinotecan with 5-fluorouracil and leucovorin (5-Fu/Lv). Patients with previously untreated advanced GC were randomly assigned to start with docetaxel 45 mg/m2 (arm T) or irinotecan 180 mg/m2 (arm C) with bolus and 44 h infusion of 5-Fu/Lv (D1, q2 weeks). After four courses, there was a prescheduled crossover to the alternative regimen for four additional courses. QoL was measured with the EORTC QLQ-C30 questionnaire at the start of the treatment, at crossover and after completing treatment with both regimens. Eighty-one patients were randomized, and 78 patients started treatment. A total of 191 completed QoL questionnaires were collected. There were no statistically significant differences in QoL scores between the two treatment groups and no changes in mean scores during the 16 weeks of treatment. During the last 8 weeks of treatment, a significantly larger portion of patients with radiological response reported sustained or better QoL scores than those with no radiological response (82 vs. 50 %, p = 0.007). Chemotherapy in advanced GC did not affect QoL average scores. Patients with non-responding tumours reported more often a decline in the global QoL score. The concept of the pre-scheduled switch of chemotherapy regimens prior to progression should be further studied in this disease, as it appears effective, tolerable and not to negatively affect QoL.

Keywords

QoL Quality of life Gastric cancer Palliative chemotherapy Docetaxel Irinotecan 

Notes

Acknowledgments

Financial support from the Swedish Cancer Society (Cancerfonden), Sanofi-Aventis and Pfizer.

Conflict of interest

None.

References

  1. 1.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van CJ, de Velde M, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi: 10.1056/NEJMoa055531.PubMedCrossRefGoogle Scholar
  2. 2.
    Macdonald JS. Adopting postoperative chemoradiotherapy in resected gastric cancer. Gastrointest Cancer Res. 2009;3(6):245–6.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30. doi: 10.1056/NEJMoa010187.PubMedCrossRefGoogle Scholar
  4. 4.
    Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21. doi: 10.1200/JCO.2010.33.0597.PubMedCrossRefGoogle Scholar
  5. 5.
    Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9. doi: 10.1200/JCO.2005.05.0245.PubMedCrossRefGoogle Scholar
  6. 6.
    Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010;116(11):2511–8. doi: 10.1002/cncr.25064.PubMedGoogle Scholar
  7. 7.
    Cunningham A, Rao S, Starling N. (2006) Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J Clin Oncol. 2006;24:18.Google Scholar
  8. 8.
    Van Cutsem E, Van de Velde C, Roth A, Lordick F, Kohne CH, Cascinu S, et al. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer. 2008;44(2):182–94. doi: 10.1016/j.ejca.2007.11.001.PubMedCrossRefGoogle Scholar
  9. 9.
    Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, et al. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev. 2009;35(5):451–62. doi: 10.1016/j.ctrv.2009.04.008.PubMedCrossRefGoogle Scholar
  10. 10.
    Gubanski M, Johnsson A, Fernebro E, Kadar L, Karlberg I, Flygare P, et al. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer. 2010;13(3):155–61. doi: 10.1007/s10120-010-0553-4.Google Scholar
  11. 11.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.PubMedCrossRefGoogle Scholar
  12. 12.
    Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–44.PubMedGoogle Scholar
  13. 13.
    Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25(22):3210–6. doi: 10.1200/JCO.2006.08.3956.PubMedCrossRefGoogle Scholar
  14. 14.
    Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study—FFCD 9803. J Clin Oncol. 2004;22(21):4319–28. doi: 10.1200/JCO.2004.01.140.PubMedCrossRefGoogle Scholar
  17. 17.
    Park SH, Lee WK, Chung M, Lee Y, Han SH, Bang SM, et al. Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs. 2006;17(2):225–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20(8):1996–2004.Google Scholar
  19. 19.
    Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, et al. A multicentre, randomized phase III trial comparing protracted venous infusion (PVI) 5-flurorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol. 2002;13(10):1568–75.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Oncology and PathologyKarolinska IntitutetStockholmSweden
  2. 2.Department of Radiology, Oncology and Radiation ScienceUniversity of UppsalaUppsalaSweden
  3. 3.Centre for Clinical Research SörmlandUppsala UniversityUppsalaSweden

Personalised recommendations